Orexigen Therapeutics, Inc. (NASDAQ: OREX) reported Q3 EPS of ($0.19), $0.01 worse than the analyst estimate of ($0.18). Revenue for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE